New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) in...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kazuhiko Uchiyama, Tomohisa Takagi, Yasunori Iwamoto, Norihiko Kondo, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiro Katada, Osamu Handa, Takeshi Ishikawa, Hiroaki Yasuda, Junichi Sakagami, Hideyuki Konishi, Nobuaki Yagi, Yuji Naito, Yoshito Itoh
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2014
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975

Documents similaires